Viekira OK'd; AbbVie prices under Gilead's Harvoni
This article was originally published in Scrip
Executive Summary
Among the end-of-the-year approvals from the FDA was AbbVie's hepatitis C virus (HCV) drug Viekira Pak, whose lower price than Gilead Sciences' medicine Harvoni (ledipasvir-sofosbuvir) is bound to create more competition for the latter drug.